false
OasisLMS
Catalog
SCCM Resource Library
A Multimodal Approach: When Should We Reach Beyond ...
A Multimodal Approach: When Should We Reach Beyond Norepinephrine and Vasopressin?
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The presentation highlights the evolving strategies in the use of vasopressors, particularly focusing on the role of angiotensin II in managing hypotension and septic shock. Norepinephrine remains the recommended first-line vasopressor, with vasopressin and epinephrine suggested as subsequent additions. However, there's ongoing debate about these protocols. The ATHOS-3 clinical trial repositioned angiotensin II as an effective vasopressor, especially in patients with high-output vasopressor-refractory shock. Findings showed that patients often exhibit an imbalance in angiotensin I to II, which has implications for survival rates. Angiotensin II demonstrated improved hemodynamics and better outcomes in patients with this imbalance, especially those with lower baseline doses of other vasopressors. Additionally, angiotensin II may enhance oxygenation, offering potential benefits for those with acute respiratory distress syndrome. The discussion suggests a future in precision-based vasopressor management to more effectively target and improve patient outcomes.
Asset Caption
One-Hour Concurrent Session | Rethinking Vasopressors: Evolving Evidence and Emerging Concepts in Vasopressor Administration
Meta Tag
Content Type
Presentation
Membership Level
Professional
Membership Level
Select
Year
2024
Keywords
vasopressors
angiotensin II
hypotension
septic shock
ATHOS-3 trial
×
Please select your language
1
English